Masitinib in Refractory Active Rheumatoid Arthritis
A 24-week With Possible Extension, Prospective, Multicenter, Randomised, Double-blind, Controlled, 3-parallel Groups, Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib at 3 and 6 mg/kg/Day to Methotrexate, With a Randomisation 1:1:1, in Treatment of Patients With Active Rheumatoid Arthritis With Inadequate Response to 1. Methotrexate or to 2. Any DMARD Including at Least One Biologic Drug if Patients Previously Failed Methotrexate or to 3. Methotrexate in Combination With Any DMARD Including Biologic Drugs
Sponsor: AB Science
Terminated
Sponsor decision based on portfolio prioritization
Other terminated trials from AB Science
Other Rheumatoid Arthritis (RA) trials with similar outcome
Listed as NCT01410695, this PHASE2/PHASE3 trial focuses on Rheumatoid Arthritis (RA) and remains terminated or withdrawn. Sponsored by AB Science, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2019 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
Status: Unknown Status → Terminated
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Unknown Status PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2_PHASE3
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AB Science
For direct contact, visit the study record on ClinicalTrials.gov .